

Ref. No. JPL/CS/1756/2022

Date: 11th February, 2022.

To
BSE Ltd.
P.J. Towers, Dalal Street,
Mumbai - 400 001.

Sub.: **Outcome of Board Meeting held today, i.e. 11th February, 2022- Standalone Unaudited Financial Results for the quarter and nine months ended on 31st December, 2021.**

Reg.: **Regulation 30(2) & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**


Dear Sir,

1. The Standalone Unaudited Financial Statments for the quarter and nine months ended on 31st December, 2021 have been approved and adopted by the Board, on the recommendation of Audit Committee, vide their respective meeting held on even date. The same has been attached herewith in the format required under Regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
2. The Limited Audit Review Report of Auditors of the Company, on the standalone unaudited financial results for the quarter ended on 31st December, 2021, is also attached.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,
For Jenburkt Pharmaceuticals Limited,



ASHISH R. SHAH
Company Secretary and Compliance officer.

Encl.: As stated above.

Statement of Unaudited Standalone Financial Results for the Quarter and Nine Months ended on 31st Dec, 2021

(Rs. in Lacs other than EPS)

	Particulars	Quarter Ended			Year To Date		Year Ended
		31-12-2021	30-09-2021	31-12-2020	31-12-2021	31-12-2020	31-03-2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	3300.21	3550.84	3181.88	9569.03	7973.47	10929.42
II	Other Income	128.50	119.06	105.02	367.05	304.87	430.85
III	Total income (I + II)	3428.71	3669.90	3286.90	9936.08	8278.34	11360.27
IV	Expenses						
	(a) Cost of Materials Consumed	344.35	264.16	193.93	887.70	485.84	678.01
	(b) Purchase of Stock-in-trade	622.98	586.23	501.09	1659.42	1686.18	2013.43
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-162.79	46.52	221.41	-137.76	86.42	318.39
	(d) Employee benefit expenses	962.37	911.67	845.51	2738.55	2447.21	3237.71
	(e) Finance Costs	10.09	10.91	11.74	31.32	35.25	47.37
	(f) Depreciation and Amortisation Expense	47.29	45.35	50.81	136.05	150.79	203.54
	(g) Other expenses	835.94	715.41	718.26	2160.89	1786.32	2697.65
	Total Expenses (IV)	2660.23	2580.25	2542.75	7476.17	6678.01	9196.10
V	Profit before tax (III - IV)	768.48	1089.65	744.15	2459.91	1600.33	2164.17
VI	Tax Expense						
	(i) Current Tax	150.00	300.00	135.00	600.00	365.00	544.50
	(ii) Income Tax for previous years	0.00	0.00	0.00	-7.21	8.51	8.51
	(iii) Deferred Tax	-4.23	-7.39	14.56	-17.72	-35.75	-39.08
VII	Profit after tax for the period (V-VI)	622.71	797.04	594.59	1884.84	1262.57	1650.24
VIII	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-15.39	62.56	108.50	93.24	208.50	219.54
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	1.78	-7.07	17.43	-10.59	35.49	-23.58
	B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
IX	Total Comprehensive Income for the period (VII + VIII)	609.10	852.53	720.52	1967.49	1506.56	1846.20
	Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	458.94	458.94	458.94	458.94	458.94
X	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	13.57	17.37	12.96	41.07	27.51	35.96

Notes:

- The above statement of unaudited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th February, 2022.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The figures of the previous year/period have been regrouped/rearranged to render them comparable with the figures of the current period.
- The Statement of Assets And Liabilities and Cashflow Statement as at 30th Sept 2021 are annexed as Annexure A & B respectively.

 By order of the Board
 For Jenburkt Pharmaceuticals Ltd.


 (Ashish U. Bhuta)
 Chairman & Managing Director

Place : Mumbai

Date : 11th February, 2022

Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9TH FLOOR, TARDEO CIRCLE, MUMBAI - 400034
TEL: 23513758 / 23520330 FAX: 66607263, 9322508373

Email ID: vikram@drmehta.in, ashok@drmehta.in

Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015

To the Board of Directors of
Jenburkt Pharmaceuticals Limited

We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 31st December 2021 (‘the statement’).


This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,
Chartered Accountants
(Firm Reg. No. 106207W)



Partner
Ashok Mehta
(Membership No. 101746)
UDIN: 22101746ABJEY99886
Place: Mumbai
Date: 11th February, 2022

